Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-04-2009 | Epidemiology

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

Authors: Heather-Jane Au, Kamran Golmohammadi, Tallal Younis, Shailendra Verma, Stephen Chia, Konrad Fassbender, Philip Jacobs

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Purpose BCIRG 001 demonstrated prolonged disease-free (DFS) and overall survival (OS) but increased toxicity for adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in women with node positive breast cancer (BC). This study evaluates quality-adjusted survival and cost-effectiveness of adjuvant TAC versus FAC, taking downstream decisions and events into account, including palliative chemotherapy with taxanes. Methods We developed a Markov model for a cohort of women with node positive BC eligible for adjuvant anthracyclines. Data input included clinical and resource utilization data collected prospectively from BCIRG 001. Treatment decisions and outcomes with disease recurrence were based on a systematic literature review with validity reviewed by a national panel of Canadian BC oncologists. Direct costs for resource utilization following Canadian practice patterns were included. Unit costs were obtained from provincial cost list and published drug list prices. Utility scores were derived from the literature. An incremental cost-effectiveness ratio (ICER) in cost per quality-adjusted life-years (QALY) gained for TAC versus FAC was calculated. Results For 1,000 women with node positive BC, the model showed that TAC would lead to a gain of 313 QALY (370 life years) at an additional cost of $5.8 Million Canadian dollars (Cdn) compared to FAC, over a 10-year time horizon. The ICER of TAC versus FAC was $18,505.54 Cdn per QALY gained. Sensitivity analyses supported the robustness of the model. By one-way sensitivity analyses of over 50 model variables, 95% of the cumulative ICER variation was from $6,000 to $28,000 Cdn/QALY. By multivariate Monte Carlo simulation, there was a 70% probability that the ICER would be under $50,000 CdN/QALY. Conclusion For women with node positive BC, TAC improves DFS and OS compared to FAC and is a cost-effective adjuvant chemotherapy strategy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Canadian Cancer Society/National Cancer Institute of Canada (2006) Canadian cancer statistics 2006, Toronto, Canada Canadian Cancer Society/National Cancer Institute of Canada (2006) Canadian cancer statistics 2006, Toronto, Canada
2.
go back to reference Harris JR, Lippman ME, Morrow M et al (1996) Prognostic and predictive factors in diseases of the breast. Lippincott-Raven Publishers, Philadelphia, pp 461–485 Harris JR, Lippman ME, Morrow M et al (1996) Prognostic and predictive factors in diseases of the breast. Lippincott-Raven Publishers, Philadelphia, pp 461–485
3.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717CrossRef
4.
go back to reference Adjuvant Therapy for Breast Cancer (2000) NIH consensus statement online. November 1–3; cited 2006, June 21, 17(4):1–23 Adjuvant Therapy for Breast Cancer (2000) NIH consensus statement online. November 1–3; cited 2006, June 21, 17(4):1–23
5.
go back to reference O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(suppl 3):20–29PubMedCrossRef O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(suppl 3):20–29PubMedCrossRef
6.
go back to reference Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRef Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRef
7.
go back to reference Blum JL, Dieras V, Mucci Lo Russo P et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768PubMedCrossRef Blum JL, Dieras V, Mucci Lo Russo P et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768PubMedCrossRef
8.
go back to reference Zelek I, Barthier S, Riofrio M et al (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267–2272PubMedCrossRef Zelek I, Barthier S, Riofrio M et al (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267–2272PubMedCrossRef
9.
go back to reference Jones S, Erban J, OVermoyer B et al (2003) Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Presented at the 26th annual San Antonio breast cancer symposium Jones S, Erban J, OVermoyer B et al (2003) Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Presented at the 26th annual San Antonio breast cancer symposium
10.
go back to reference Papaldo P, Fabi A, Nardoni C et al (2003) Trastuzumab improves the prognosis in HER2-positive when compared with HER2-negative patients. Trastuzumab plus vinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients. Breast Cancer Res Treat 82(suppl 1):S9 Papaldo P, Fabi A, Nardoni C et al (2003) Trastuzumab improves the prognosis in HER2-positive when compared with HER2-negative patients. Trastuzumab plus vinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients. Breast Cancer Res Treat 82(suppl 1):S9
11.
go back to reference Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef
12.
go back to reference Martin M, Pienkowski T, Mackey J et al (2003) TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients. BCIRG 001: 55 months followup. Presented at the 26th annual San Antonio breast cancer symposium Martin M, Pienkowski T, Mackey J et al (2003) TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients. BCIRG 001: 55 months followup. Presented at the 26th annual San Antonio breast cancer symposium
13.
14.
go back to reference Bedwinek J (1994) Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 4:260–269PubMedCrossRef Bedwinek J (1994) Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 4:260–269PubMedCrossRef
15.
go back to reference Clemons M, Danson S, Hamilton T et al (2001) Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 27:67–82PubMedCrossRef Clemons M, Danson S, Hamilton T et al (2001) Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 27:67–82PubMedCrossRef
16.
go back to reference Zielilnski CC (2003) Treatment choices for second-line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 81(suppl 1):S33–S36CrossRef Zielilnski CC (2003) Treatment choices for second-line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 81(suppl 1):S33–S36CrossRef
17.
go back to reference Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322–338PubMedCrossRef Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322–338PubMedCrossRef
18.
go back to reference Crown J, Dieras V, Kaufmann M et al (2002) Chemotherapy for metastatic breast cancer—report of a European expert panel. Lancet Oncol 3:719–727PubMedCrossRef Crown J, Dieras V, Kaufmann M et al (2002) Chemotherapy for metastatic breast cancer—report of a European expert panel. Lancet Oncol 3:719–727PubMedCrossRef
19.
go back to reference Fassbender K, Fainsinger R, Brenneis C et al (2005) Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993–2000. Palliat Med 19:513–520PubMedCrossRef Fassbender K, Fainsinger R, Brenneis C et al (2005) Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993–2000. Palliat Med 19:513–520PubMedCrossRef
20.
go back to reference Brown RE, Hutton J, Burrell A (2001) Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091–1102PubMedCrossRef Brown RE, Hutton J, Burrell A (2001) Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091–1102PubMedCrossRef
21.
go back to reference Hayman JA, Hillner BE, Harris JR et al (2000) Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol 16:1022–1029 Hayman JA, Hillner BE, Harris JR et al (2000) Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol 16:1022–1029
22.
go back to reference Leung PP, Tannock IF, Oza AM et al (1999) Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 17:3082–3090PubMed Leung PP, Tannock IF, Oza AM et al (1999) Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 17:3082–3090PubMed
23.
go back to reference Brown RE, Hutton J (1998) Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 9:899–907PubMedCrossRef Brown RE, Hutton J (1998) Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 9:899–907PubMedCrossRef
24.
go back to reference Martin SC, Gagnon DD, Zhang L et al (2003) Cost-utility analysis of survival with epoetin-alpha versus placebo in stage IV breast cancer. Pharmacoeconomics 21:1153–1169PubMedCrossRef Martin SC, Gagnon DD, Zhang L et al (2003) Cost-utility analysis of survival with epoetin-alpha versus placebo in stage IV breast cancer. Pharmacoeconomics 21:1153–1169PubMedCrossRef
25.
go back to reference Drummond MF, Scupher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University press, Oxford Drummond MF, Scupher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University press, Oxford
26.
go back to reference Case Mix number 297, Alberta Health and Wellness, costs in Alberta, 2002 Case Mix number 297, Alberta Health and Wellness, costs in Alberta, 2002
27.
go back to reference Hurley SF, Huggins RM, Snyder RD et al (1992) The cost of breast cancer recurrences. Br J Cancer 65:449–455PubMed Hurley SF, Huggins RM, Snyder RD et al (1992) The cost of breast cancer recurrences. Br J Cancer 65:449–455PubMed
28.
go back to reference Martin M, Lluch A, Segui MA (2004) Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. J Clin Oncol; 22(suppl 14):620. Proc ASCO (Post-Meeting Edition) Martin M, Lluch A, Segui MA (2004) Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. J Clin Oncol; 22(suppl 14):620. Proc ASCO (Post-Meeting Edition)
29.
go back to reference Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trustuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trustuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef
30.
go back to reference Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRef Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRef
31.
go back to reference TreeAge software Inc. (2005) Williamstown, MA TreeAge software Inc. (2005) Williamstown, MA
32.
go back to reference Hirth RA, Chernew ME, Miller E et al (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Health Econ 20:332–342 Hirth RA, Chernew ME, Miller E et al (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Health Econ 20:332–342
33.
go back to reference Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook, 6th edn. Springer, New York Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook, 6th edn. Springer, New York
34.
go back to reference Smith TJ, Khatcheressian J, Lyman GH (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guidelines. J Clin Oncol 24:3187–3205PubMedCrossRef Smith TJ, Khatcheressian J, Lyman GH (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guidelines. J Clin Oncol 24:3187–3205PubMedCrossRef
35.
go back to reference Hillner BE, Weeks JC, Desch CE et al (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72–79PubMed Hillner BE, Weeks JC, Desch CE et al (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72–79PubMed
36.
go back to reference Neyt M, Albrecht J, Cocquyt V (2006) An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 17:381–390PubMedCrossRef Neyt M, Albrecht J, Cocquyt V (2006) An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 17:381–390PubMedCrossRef
37.
go back to reference Elkin EB, Weinstein MC, Winer EP et al (2004) HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22:854–863PubMedCrossRef Elkin EB, Weinstein MC, Winer EP et al (2004) HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22:854–863PubMedCrossRef
38.
go back to reference Hillner BE, Schrag D, Sargent DJ et al (2005) Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 104:1871–1084PubMedCrossRef Hillner BE, Schrag D, Sargent DJ et al (2005) Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 104:1871–1084PubMedCrossRef
39.
go back to reference Rocconi RP, Case AS, Straughn JM et al (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer 107:536–543PubMedCrossRef Rocconi RP, Case AS, Straughn JM et al (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer 107:536–543PubMedCrossRef
40.
go back to reference Ubel PA, Hirth RA, Chernew ME et al (2003) What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 163:1637–1641PubMedCrossRef Ubel PA, Hirth RA, Chernew ME et al (2003) What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 163:1637–1641PubMedCrossRef
41.
go back to reference Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506PubMedCrossRef Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506PubMedCrossRef
Metadata
Title
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
Authors
Heather-Jane Au
Kamran Golmohammadi
Tallal Younis
Shailendra Verma
Stephen Chia
Konrad Fassbender
Philip Jacobs
Publication date
01-04-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0034-1

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine